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Abstract
Objective:  To  assess  the  value  of  magnetic  resonance  cholangiography  with  gadobenate  dimeg-
lumine (Gd-BOPTA)  where  there  is  a  suspicion  of  bile  leakage  in  the  post-liver  transplant
patient.
Patients and  methods:  Eight  patients  who  had  undergone  a  liver  transplant  underwent  14  MR
cholangiograms,  ﬁve  of  whom  presented  bile  leakage  while  the  other  three  had  no  biliary  system
complications.  The  results  were  compared  to  conventional  bile  duct  opaciﬁcation  (by  endoscopy
or t-tube  cholangiogram).  The  analysis  covered  whether  there  was  opaciﬁcation  of  the  common
bile duct  and  intrahepatic  bile  ducts  on  T1-weighted  sequences  after  an  injection  of  Gd-BOPTA
on delayed  biliary  excretion  phase  sequences  that  were  carried  out  on  average  74  min  after  the
injection.  Enhancing  perihepatic  collections  were  also  taken  into  account.
Results: Opaciﬁcation  of  the  bile  ducts  on  delayed-phase  MR  cholangiogram  sequences  was
always seen  in  the  absence  of  bile  leakage,  and  was  never  found  when  leakage  was  present.
Enhancing perihepatic  collections  pointed  to  bile  leakage  every  time.
Conclusion:  Gd-BOPTA-enhanced  MR  cholangiography  is  a  simple  and  non-invasive  technique  for
detecting  bile  leakage  in  the  post-liver  transplant  patient.
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Complications  of  the  biliary  system  are  foremost  in  the
mmediate  and  later  recovery  period  from  a  liver  transplant,
een  in  10—30%  of  cases  [1,2]. The  most  common  complica-
ion  is  bile  duct  stricture  (16%),  followed  by  bile  leakage
11%)  [3].  The  clinical  symptoms  (bile  externalised  via  a
rain  or  through  the  scar,  abdominal  pain,  jaundice,  fever)
nd  abnormal  laboratory  ﬁndings  (cytolysis  and  cholesta-
is)  are  signs  that  are  sensitive,  though  not  very  speciﬁc,
or  conﬁrming  the  presence  of  an  anastomotic  bile  leakage
Fig.  1).
There  are  two  ways  in  which  to  make  a  diagnosis.  On  the
ne  hand,  there  are  the  non-invasive  but  minimally  speciﬁc
nvestigations  including  sonography,  computed  tomography
CT),  MRI  with  or  without  gadolinium  chelates,  and  opaci-
cation  by  t-tube  cholangiogram,  and  on  the  other,  there
re  invasive  investigations  such  as  endoscopic  retrograde  or
ercutaneous  transhepatic  cholangiography,  which  remain
he  gold  standard  techniques.  The  ﬁrst  group  of  tech-
iques  lack  speciﬁcity  as  they  usually  show  subhepatic
r  perianastomotic  ‘‘collections’’  while  the  second  group,
nd  endoscopic  retrograde  cholangiography  in  particular,
arry  a  risk  of  haemorrhage  (1.13%),  pancreatitis  (1.8%),
nd  infection,  and  they  are  still  not  of  perfect  sensitiv-
ty  [4,5].
Since  mangafodipir  trisodium  (Teslascan® GE  Healthcare,
rinceton,  NJ)  was  withdrawn  from  the  market  in  2006
6],  the  use  of  hepatocyte-speciﬁc  gadolinium  chelates
hat  are  in  part  excreted  through  the  biliary  tract  in
his  indication  has  been  minimally  reported  in  the  litera-
ure.
The  purpose  of  this  article  is  to  report  our  experience
f  using  gadobenate  dimeglumine  (Gd-BOPTA)  (MultiHance®;
racco  Diagnostics  Inc.,  Princeton,  NJ),  the  only  hepatocyte-
peciﬁc  gadolinium  chelate  that  is  currently  available  in
rance,  in  order  to  detect  bile  leakage  in  liver  transplant
atients  using  a  non-invasive  method.
igure 1. Duct-to-duct biliary anastomosis preserving the cystic
uct stumps with or without Kehr’s t-tube (in red).
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atients and methods
atients
etween  June  2010  and  March  2012,  32  liver  transplants
ere  carried  out  at  our  centre.  Fourteen  gadobe-
ate  dimeglumine-enhanced  (Gd-BOPTA,  MultiHance®) MR
holangiograms  were  carried  out  in  eight  patients  who  had
ndergone  liver  transplant  for  the  following  reasons:  three
ases  of  alcoholic  cirrhosis,  two  cases  of  decompensated
epatitis  C  cirrhosis,  one  of  hepatocellular  carcinoma  in
lcoholic  cirrhosis,  one  of  fulminant  hepatitis,  and  one  of
brolamellar  carcinoma.  The  patients  were  four  males  and
our  females  with  a  mean  age  of  47  (27—63  years)  (Table  1).
All  of  the  patients  showed  clinical  signs/laboratory  study
esults  suggestive  of  a  bile  leakage.  Six  patients  out  of  eight
ad  had  a  CT  scan  and  all  had  had  a  sonogram  initially,
howing  perihepatic  collections  and  an  absence  of  bile  duct
ilation.
The  MR  cholangiogram  was  carried  out  on  average  26  days
17—41  days)  after  the  transplant.
Of  these  eight  patients,  ﬁve  presented  a bile  leak:  four
ilar  leaks  (anastomotic  or  cystic)  conﬁrmed  by  endoscopic
etrograde  cholangiography,  and  one  leak  along  the  cut  edge
f  a  partial  transplant  (donor  right  lobe  in  a small  stature
ecipient)  conﬁrmed  by  t-tube  cholangiography  followed  by
omputed  tomography.
Therapeutic  management  consisted  of  ﬁtting  one  or  sev-
ral  endostents  via  retrograde  endoscopy  for  the  patients
ho  presented  an  anastomotic  bile  leakage  at  the  hilum
nd  monitoring  for  the  patient  who  presented  a  leak  at
he  cut  edge  of  the  lobectomy.  During  the  recovery  period,
ll  of  the  patients  gradually  improved  in  terms  of  clinical
igns  and  laboratory  ﬁndings,  with  resolution  of  the  bile  leak
onﬁrmed  using  the  same  imaging  modality  that  led  to  diag-
osis,  on  average  nine  weeks  (extreme  values  of  5  and  12
eeks)  after  the  endoscopy  treatment.  The  endostents  were
emoved  after  the  repeat  examination.
ethods
ll  of  the  MR  cholangiograms  were  carried  out  using  a  1.5
esla  system  (Optima  MR450  W,  GE  medical  systems,  Mil-
aukee,  Wis)  with  a  phased-array  coil.  The  patients  were
laced  in  the  dorsal  decubitus  position  with  respiratory  mon-
toring  and  no  premedication  except  for  consumption  of
ineapple  juice  before  the  examination  in  order  to  block
ut  the  signal  from  gastric  juices.  The  protocol  consisted
f  axial  and  coronal  single  shot  fast  spin  echo  (SSFSE)
2-weighted  sequences  during  breath-hold  (TE  =  102  ms,  TR
50  ms,  slices  4  mm  thick,  matrix  512  × 512),  a  3D  MR  cholan-
iography  sequence  and  thick  sequential  slices  in  2D  MR
holangiography  in  the  coronal  oblique  plane  (TE  =  581  ms,
R  =  6000  ms,  slices  20  mm  thick),  and  T1-weighted  LAVA
lex  sequences  (Liver  Acquisition  with  Volume  Acceleration)
ith  fat  saturation,  both  with  and  without  contrast  injec-
ion  (TE  =  3.1  ms,  TR  =  6.05  ms,  slices  4  mm  thick,  matrix
12  ×  512).  This  sequence  was  carried  out  at  T  =  0,  T  =  30  s, =  80  s,  T  =  4  min,  T  =  12  min.  Finally,  a delayed-phase  acqui-
ition  known  as  the  biliary  sequence  was  carried  out  at
 =  74  min  on  average  [45—120  min]  after  the  injection  of  Gd-
OPTA  (MultiHance®),  which  allowed  the  biliary  excretion
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Table  1  Detail  of  patients  in  the  study  and  their  evolution.
Patients  Indication  for
transplant
Initial  MR
cholangiogram
Cholangiogram  Treatment
1  Fibrolamellar
carcinoma
Whole  liver
D  +  22
Opaciﬁcation  of  IHBD
and  CBD
No  enhancing
perihepatic
collections
D +  23
ERC
No  bile  leakage
2 Alcoholic  cirrhosis
(alcohol  stopped)
Whole  liver
D  +  41
Opaciﬁcation  of  IHBD
and  CBD
No  enhancing
perihepatic
collections
D +  46
ERC
No  bile  leakage
3
Fig.  1
Alcoholic  cirrhosis
(alcohol  stopped)
Whole  liver
D  +  20
Opaciﬁcation  of  IHBD
and  CBD
No  enhancing
perihepatic
collections
D +  21
ERC
No  bile  leakage
4
Figs.  2  and  3
Fulminant  hepatitis
Partial  transplant
(left  hepatectomy)
D  +  18
No  opaciﬁcation  of  BD
Hilar  and  perihepatic
enhancement
D  +  16
Opaciﬁcation  study
by  t-tube
cholangiogram,  then
CT
Bile  leakage  along
the  hepatectomy
line
Monitoring
Repeat MR  cholangiogram  at
3  then  6  weeks,  then  t-tube
cholangiogram  with
opaciﬁcation  showing  no
further  bile  leak  at  6  weeks
5
Fig.  4
Alcoholic  cirrhosis
(alcohol  stopped)
Whole  liver
D  +  38
No  opaciﬁcation  of  BD
Hilar  and  perihepatic
enhancement
D  +  40
ERC
Bile  leakage  from
the  native  cystic
duct  stump
Metal  endostent  placed  in
situ,  removed  10  weeks  later
Repeat  MR  cholangiogram
showing  good  opaciﬁcation  of
the  CBD
6
Fig.  5
Chronic  HCV
cirrhosis
Whole  liver
D  +  35
No  opaciﬁcation  of  BD
Hilar  and  perihepatic
enhancement
D  +  36
ERC
Anastomotic  bile
leakage
Metal  endostent  placed  in
situ,  MR  cholangiogram
carried  out  5  weeks  later  no
longer  found  signs  suggestive
of  a  leak,  meaning  the
endostent  could  be  removed
7  HCC  complicating
alcoholic  cirrhosis
Whole  liver
D  +  19
No  opaciﬁcation  of  BD
Hilar  and  perihepatic
enhancement
D  +  23
ERC
Hilar  bile  leakage
Plastic  endostent  placed  in
situ,  then  replaced  by  a
metal  one,  removed  12
weeks  later
MR  cholangiogram  carried  out
after  this  no  longer  found  a
leak
8  Alcoholic  and  HCV
cirrhosis
Whole  liver
D  +  17
No  opaciﬁcation  of  BD
Hilar  and  perihepatic
enhancement
D  +  18
ERC
Anastomotic  bile
leakage
Metal  endostent  placed  in
situ,  removed  11  weeks  later
Repeat  MR  cholangiogram
showing  good  opaciﬁcation  of
the  CBD
ERC: endoscopic retrograde cholangiography; IHBD: intrahepatic bile ducts; CBD: common bile duct; BD: bile ducts; HCC: hepatocellular
carcinoma.
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roperties  of  this  gadolinium  chelate  to  be  exploited.  In
etween  the  two  sequences  at  4  and  12  min,  a  T2-weighted
SE  Fat  Sat  sequence  was  taken  (TE  =  92  ms,  TR  9230  ms,
lices  5  mm  thick).
The  dose  of  gadobenate  dimeglumine  (Gd-BOPTA)
MultiHance®)  injected  was  0.05  mmol/kg  of  body  weight,
r  0.1  ml/kg  at  a  rate  of  2  ml/s,  mean  dose  of  12  cc
6—16  cc].
The  MR  cholangiograms  were  interpreted  by  two  gas-
roenterological  and  hepatobiliary  radiologists  working
ogether.  There  were  three  signs  that  they  looked  for  in  each
ase:  opaciﬁcation  of  the  common  bile  duct  on  the  delayed-
hase  biliary  acquisition;  opaciﬁcation  of  the  intrahepatic
iliary  tree  on  the  delayed-phase  acquisition;  delayed-phase
nhancement  of  hilar  or  perihepatic  collections,  demon-
trated  using  measurements  of  signal  intensity  in  the  ROI.
esults
ll  the  examinations  were  considered  possible  to  interpret  in
pite  of  the  presence  of  a  few  metal  artifacts  (staples  in  six
ases,  and  coils  in  one  patient  who  underwent  examination
wice)  and  respiratory  artifacts.
The  three  patients  who  did  not  present  bile  leakage  all
howed  opaciﬁcation  of  the  common  bile  duct  and  the  prox-
mal  biliary  tree  as  far  as  the  second  order  intrahepatic  bile
ucts.  No  enhancing  perihepatic  collections  were  demon-
trated  in  these  patients  (Fig.  2).
Of  the  ﬁve  patients  who  did  present  bile  leakages,  none
resented  delayed-phase  visualisation  of  the  biliary  tree
r  opaciﬁcation  of  the  common  bile  duct,  irrespective  of
hether  the  origin  of  the  leak  was  anastomotic,  cystic,  or
t  the  cut  edge  of  the  hepatectomy  (Figs.  3  and  4).  Four  of
hese  ﬁve  patients  showed  signiﬁcantly  enhancing  hilar  and
erihepatic  collections  (Fig.  5).
Once  the  leak  was  treated  or  stemmed,  repeat  MRI  scans
ere  carried  out  on  average  9  weeks  later  (5—12  weeks),
nd  these  showed  that  the  common  bile  duct  had  become
paque  and  there  was  an  absence  of  residual  enhancing  hilar
nd  perihepatic  ﬂuid  collections.
iscussion
ostoperative  bile  leakages  pose  a  real  problem  of  diagnosis
n  liver  transplant  patients.  They  are  a  common  compli-
ation  (11%  in  the  literature  [3]  and  15%  in  our  study)  in
eakened  patients,  with  a  clinical  presentation  and  labora-
ory  study  results  that  are  sensitive  but  non-speciﬁc.
The  value  of  gadolinium-based  contrast  agents  with  hepa-
obiliary  speciﬁcity  has  been  broadly  proven  in  terms  of
dentifying  and  characterising  hepatic  lesions,  as  well  as  for
he  morphological  exploration  of  the  bile  ducts  [7,8].
In  the  context  of  MR  cholangiography,  they  are  useful
or  their  properties  of  hepatobiliary  excretion,  which  enable
n  acquisition  combining  the  morphological  features  of  MRI
ith  the  functional  information  of  bile  duct  studies.
The  standard  MR  cholangiogram  demonstrates  indirectigns  relating  to  the  presence  of  effusion  or  perihepatic
ollections  and  these  require  careful  interpretation  in  the
ost-transplant  context,  as  they  could  be  residual  ascites,
ostoperative  collections,  or  localised  collections  of  bile
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biloma).  In  contrast,  hepatobiliary  excretion  demonstrates
 direct  sign  (opaciﬁcation  of  the  bile  ducts  or  collections)
Fig.  6).
In  our  study,  the  patients  that  did  not  present  bile  leak-
ges,  or  who  had  been  previously  treated  with  a  biliary
tent,  presented  opaciﬁcation  of  the  common  bile  duct  and
he  proximal  biliary  tree.  By  contrast,  none  of  the  patients
ho  did  have  a  bile  leakage,  irrespective  of  its  origin,  pre-
ented  bile  duct  opaciﬁcation  and  almost  none  of  them  (4/5)
resented  enhancing  hilar  or  perihepatic  collections.  The
adolinium  chelate  excreted  seemed  to  leak  into  the  col-
ections  rather  than  stagnating  in  the  bile  ducts.
The  use  of  gadobenate  dimeglumine  (MultiHance®)  does
ot  compromise  liver  function  [9—11]. This  means  that  it
s  possible  to  use  this  product  in  patients  in  the  periop-
rative  period  of  a  liver  transplant  while  still  respecting
he  usual  limitations  regarding  renal  function  and  the
isk  of  nephrogenic  systemic  ﬁbrosis  in  patients  with
evere  acute  or  chronic  renal  failure  (creatinine  clear-
nce  <  30  mL/min/1.73m2),  given  that  there  is  a  higher
ncidence  of  acute  renal  failure  in  this  group.
Gadobenate  dimeglumine  is  a  gadolinium-based  contrast
roduct  that  is  hepatobiliary  tract-speciﬁc  and  it  has  two
mportant  properties:  ﬁrstly,  it  can  diffuse  into  the  extra-
ellular  space,  while  secondly  it  is  actively  transported  into
epatocytes  and  subsequently  excreted  in  the  bile  at  a  rate
f  up  to  3—5%  of  the  total  dose  [12].
A dose  of  0.05  mmol/kg  of  body  weight  or  0.1  mL/kg  is
ecommended  for  the  detection  or  monitoring  of  primary
epatic  lesions  or  hepatic  tumours  [13,14], which  equates
o  half  of  the  dose  recommended  for  exploring  the  central
ervous  system  and  in  MRA.  This  half-dose  is  made  possible
y  the  increased  relaxivity  of  gadobenate  dimeglumine  in
omparison  to  other  extracellular  gadolinium-based  agents,
robably  due  to  its  weak  capacity  to  bind  with  albumin
15]. In  our  experience,  for  patients  with  satisfactory  renal
unction  and  in  view  of  the  low  biliary  excretion  rate,  it
s  preferable  to  use  a  dose  of  0.1  mmol/kg  or  0.2  mL/kg  to
btain  satisfactory  biliary  excretion  that  is  visible  either  in
he  form  of  opaciﬁcation  of  the  common  bile  duct  and  visual-
sation  of  the  biliary  tree,  or  in  the  form  of  signiﬁcantly
nhancing  perihepatic  collections  of  bile.
It  is  possible  to  take  T1-weighted  acquisitions  during
he  biliary  excretion  phase  between  45  and  120  min  after
he  injection  while  achieving  sufﬁcient  enhancement.  In
ur  experience,  acquisitions  taken  at  between  55  and
5  minutes  provide  the  best  diagnostic  information.
Since  the  withdrawal  from  the  market  in  2006  of  Man-
afodipir  trisodium  (Teslascan® GE  Healthcare,  Princeton,
J)  which  had  a  biliary  excretion  rate  of  59%,  the  only
adolinium-based  agent  that  is  in  part  excreted  via  the
iliary  tract  that  is  available  in  France  is  gadobenate  dimeg-
umine  (MultiHance®).  There  is  one  ﬁnal  agent  that  is
ot  available  in  France:  gadoxetic  acid  (Primovist® Bayer
ealthcare),  which  has  a  50%  biliary  excretion  rate  [16].
n  contrast  to  Mangafodipir  trisodium  (Teslascan®),  for
hich  there  is  plenty  of  literature  concerning  this  indi-
ation,  the  use  of  gadobenate  dimeglumine  (MultiHance®)
as  not  to  our  knowledge  been  described.  The  main  lim-
tation  on  the  usage  of  gadobenate  dimeglumine  is  that
ts  hepatobiliary  excretion  is  delayed  in  comparison  with
ther  products:  1—2  hours  for  gadobenate  dimeglumine
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Figure 2. A 49-year-old male patient, D + 20 after liver transplant. His clinical picture features cholestasis, cytolysis, a fall in haemoglobin
levels, and abdominal pain. Sonography and computed tomography found subhepatic collections without active bleeding: a: axial T2-
weighted FatSat view demonstrating a collection with high T2 signal intensity (white arrowheads); b: axial T1-weighted LavaFlex view
with fat saturation, showing this same collection with T1 isosignal intensity (white arrowheads); c: axial T1-weighted LavaFlex view with
fat saturation 57 min after injection of 10 ml of gadobenate dimeglumine does not demonstrate enhancement of this subhepatic blood-
containing collection (black arrowheads); d, e: axial and coronal T1-weighted LavaFlex MIP reconstructions in the delayed phase visualising
the common bile duct and proximal biliary tree (asterisk). The endoscopic retrograde cholangiography carried out afterwards conﬁrmed
the absence of bile leakage.
448  M.  Fontarensky  et  al.
Figure 3. A 29-year-old male patient, recipient of a partial liver transplant (left hepatectomy), who presented gradual worsening of
cutaneous and scleral jaundice and hyperbilirubinaemia up to D + 16: a: axial portal phase iodine contrast-enhanced CT image demonstrating
a collection next to the cut edge of the left hepatectomy (black arrowheads); b: t-tube cholangiogram, no bile leakage is evident from the left
bile ducts that are reported to be slightly irregular; c, d: computed tomography exploration carried out following the t-tube cholangiogram,
coronal and axial MIP reconstruction that clearly visualises the bile leakage at the cut edge of the lobectomy (white arrowheads) next to
the surgical clips.
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bMultiHance®)  as  against  15  min  for  the  previously  used  man-
afodipir  trisodium  (Teslascan®),  although  this  did  not  allow
or  dynamic  studies  of  liver  tumours  or  primary  hepatic
®esions,  and  10  min  for  gadoxetic  acid  (Primovist )  [8].
Given  the  excellent  correlation  between  bile  leakage  of
ny  origin  and  the  simple  signs  brought  together  in  our  study,
esting  in  a  larger  sample  of  patients  would  appear  to  be
n
3
a
oequired  in  order  to  conﬁrm  the  sensitivity  and  speciﬁcity  of
his  set  of  signs  (bile  duct  opaciﬁcation:  no  bile  leakage.  No
ile  duct  opaciﬁcation:  bile  leakage).  Nonetheless,  gadobe-
ate  dimeglumine’s  (MultiHance®) low  rate  of  excretion  of
—5%  of  the  total  dose  does  not,  in  our  experience,  lead  to
 precise  visualisation  of  the  path  of  the  ﬁstula  or  the  origin
f  the  leak,  as  Mangafodipir  trisodium  (Teslascan®)  did  [6].
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Figure 4. Same patient as in Fig. 2. Forty-eight hours after the cholangiogram, an MRI was carried out with 16 ml of gadobenate dimeglu-
mine and delayed-phase acquisitions taken 120 minutes after the injection: a, b: axial T2-weighted FatSat and axial T1-weighted LavaFlex
fat saturation images, showing in particular a subhepatic collection with high T2 and low T1 signal intensity (white arrowheads); c—f: axial
and coronal T1-weighted LavaFlex fat saturation images, delayed-phase acquisitions (120 min) after the gadobenate dimeglumine injection,
enhancing subhepatic and perihepatic collections (black arrowheads) and no bile duct opaciﬁcation (asterisk).
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Figure 5. 63-year-old female patient, with a hilar collection persisting at D + 38. MRI carried out with 9 ml of gadobenate dimeglumine
and delayed-phase acquisitions taken 62 minutes after the injection: a, b: axial T2-weighted FatSat and T1-weighted LavaFlex fat saturation
images demonstrating a hilar collection with high T2 and low T1 signal intensity (white arrowhead); c, d: axial reconstruction and coronal
T1-weighted LavaFlex fat saturation image, showing enhancing hilar collections (black arrowheads) and no opaciﬁcation of the common
bile duct (asterisk); e: endoscopic retrograde cholangiogram conﬁrming the presence of a bile leakage (black arrows) from the native cystic
duct stump. Following the cholangiogram, the patient was ﬁtted with a covered metal biliary stent; f: 10 weeks after the covered metal
biliary stent was ﬁtted, the patient’s improvement in terms of clinical signs and laboratory results permitted its removal. Cholangiography
no longer found a bile leakage. The MRI that was carried out subsequently with delayed-phase acquisition at 74 minutes after injection of
9 ml of gadobenate dimeglumine demonstrated that the hilar collections had regressed as well as showing opaciﬁcation of the common bile
duct, providing further conﬁrmation that the leak had resolved.
Advantages  of  gadobenate  dimeglumine-enhanced  MR  cholangiography  451
Figure 6. A 54-year-old female patient in whom monitoring using sonography and computed tomography demonstrated hilar collections,
which were associated with cholestasis and hepatic cytolysis. An MR cholangiogram was carried out at D + 35: a: MIP reconstruction of a
3D biliary MRI that clearly visualises the native ectatic bile duct and the narrow transplanted bile ducts. Perianastomotic collections are
present (white arrowhead) that probably correspond to a biloma (indirect sign of bile leakage); b: coronal T1-weighted LavaFlex image with
fat saturation, delayed-phase acquisition taken 110 min  after gadobenate dimeglumine injection showing enhancing hilar collections with
peri-biliary contrast uptake (black arrowheads) and no bile duct opaciﬁcation (asterisk) (direct signs suggestive of a leakage); c: endoscopic
retrograde cholangiography carried out at D + 36 conﬁrmed the leak and enabled an endostent to be placed in situ.
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[Conclusion
Carrying  out  a  delayed-phase  biliary  sequence  60  min  after
administration  of  gadobenate  dimeglumine  (Gd-BOPTA)
(MultiHance®),  the  only  product  currently  available  in
France  that  is  in  part  excreted  by  the  biliary  tract,  allows
bile  leakage  to  be  demonstrated  in  post-liver  transplant
patients.  Using  this  non-invasive  technique  for  diagnostic
purposes  would  allow  endoscopic  retrograde  cholangiog-
raphy  to  be  reserved  for  patients  who  need  therapeutic
management,  i.e.  those  who  require  one  or  more  biliary
endostents  to  be  inserted  once  the  leakage  is  conﬁrmed.
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